Back to Search
Start Over
High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: A retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO
- Source :
- British Journal of Haematology, British Journal of Haematology, Wiley, 2018, 182 (6), pp.807-815. ⟨10.1111/bjh.15454⟩
- Publication Year :
- 2018
-
Abstract
- IF 5.128; International audience; The role of autologous stem cell transplantation (ASCT) in patients with marginal zone lymphoma (MZL) is debatable. This study investigated the outcome and prognostic factors affecting the outcome of patients undergoing ASCT for MZL. Eligible patients had non‐transformed nodal, extra‐nodal (MALT) or splenic MZL (SMZL), aged ≥18 years, who underwent a first ASCT between1994 and 2013 and were reported to the European Society for Blood and Marrow Transplantation, Fondazione Italiana Linfomi or Gruppo Italiano Trapianto Di Midollo Osseo registries. The study included 199 patients, [111 MALT lymphoma, 55 nodal MZL (NMZL) and 33 SMZL]. Median age at transplantation was 56 years. The median number of prior therapies was 2 (range 1–8), including rituximab in 71%. 95% had chemosensitive disease. 89% received a chemotherapy‐based high‐dose regimen. There were no significant differences in patient and transplant characteristics between the 3 histological subtypes except for a lower percentage of patients previously treated with rituximab in the MALT sub‐group and more transplants performed in recent years in the other sub‐groups. After a median follow‐up of 5 years, 5‐year cumulative incidence of relapse/progression and non‐relapse mortality were 38% and 9%, respectively. Five‐year event‐free survival (EFS) and overall survival (OS) were 53% and 73%, respectively. Five‐year cumulative incidence of second malignancies was 6%. Multivariate analysis revealed age ≥65 years was associated with a shorter EFS and OS. In addition, patients with SMZL had a shorter OS than those with MALT. ASCT may provide clinical benefit in MZL patients who have failed multiple lines of chemoimmunotherapy.
- Subjects :
- Adult
Male
Oncology
medicine.medical_specialty
Autologous transplant
[SDV]Life Sciences [q-bio]
Transplantation, Autologous
03 medical and health sciences
0302 clinical medicine
Autologous stem-cell transplantation
Chemoimmunotherapy
Marginal zone lymphoma
Mucosa-associated lymphoid tissue lymphoma
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Cumulative incidence
Treatment Failure
Retrospective Studies
business.industry
Hematopoietic Stem Cell Transplantation
MALT lymphoma
Lymphoma, B-Cell, Marginal Zone
Hematology
Middle Aged
Prognosis
medicine.disease
Survival Analysis
3. Good health
Lymphoma
Transplantation
Regimen
Treatment Outcome
030220 oncology & carcinogenesis
Female
Rituximab
business
Follow-Up Studies
030215 immunology
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 00071048 and 13652141
- Database :
- OpenAIRE
- Journal :
- British Journal of Haematology, British Journal of Haematology, Wiley, 2018, 182 (6), pp.807-815. ⟨10.1111/bjh.15454⟩
- Accession number :
- edsair.doi.dedup.....2c8dd51958de652480b1d14ca17c5e82